Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Azhar M. Awan

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentRadiation & Cellular Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Azhar M. Awan, MD, specializes in treating all solid tumors and lymphomas. He is particularly skilled in the treatment of prostate cancer, soft tissue sarcomas and breast cancer. Dr. Awan is an expert in leading edge cancer treatments, including intensity-modulated radiation therapy (IMRT) and 3-D conformal radiation therapy. He also is skilled in the use of unsealed radioactive sources for treating painful bone metastases.

    Dr. Awan has been a contributing researcher in several cancer studies, including early trials that formed the basis of the multidisciplinary head and neck cancer program at the University of Chicago Medicine. These studies evaluated the combined use of radiation therapy and chemotherapy against both untreated and previously irradiated head and neck cancers, using a unique every-other-week treatment schedule. Dr. Awan also has contributed to both the Prostate Cancer Prevention Trial and the SELECT study -- an investigation of vitamin E and selenium in the possible prevention of prostate cancer.

    Dr. Awan regularly appears on the Castle Connolly Medical Ltd.'s list of "Top Doctors" in Chicago and in America.


    Collapse Biography 
    Collapse education and training
    Loyola University Chicago, Chicago, ILB.S.1978Biology
    Loyola University Stricth School of Medicine, Maywood, ILM.D.1981
    Henry Ford Hospital, Detroit, MIFlexible Internship1982
    Rush-Presbyterian St. Luke’s Medical Center, Chicago, ILResidency1985Therapeutic Radiology
    Rush-Presbyterian St. Luke’s Medical Center, Chicago, ILChief Resident1985Therapeutic Radiology

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Patel P, Aydogan B, Koshy M, Mahmud D, Oh A, Saraf SL, Quigley JG, Khan I, Sweiss K, Mahmud N, Peace DJ, DeMasi V, Awan AM, Weichselbaum RR, Rondelli D. Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2034-41. PMID: 25234438.
      View in: PubMed
    2. Jani AB, Blend MJ, Hamilton R, Brendler C, Pelizzari C, Krauz L, Sapra B, Vijayakumar S, Awan A, Weichselbaum RR. Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med. 2004 Aug; 45(8):1315-22. PMID: 15299055.
      View in: PubMed
    3. Jani AB, Al-Qamari A, Sapra B, Krauz L, Awan A, Kocherginsky M, Gillen D. Analysis of prostate-specific antigen rebound interval in patients with prostate cancer receiving hormonal therapy and external-beam radiation therapy. Clin Prostate Cancer. 2004 Jun; 3(1):43-8. PMID: 15279690.
      View in: PubMed
    4. Jani AB, Blend MJ, Hamilton R, Brendler C, Pelizzari C, Krauz L, Vijayakumar S, Sapra B, Awan A, Weichselbaum RR. Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making. J Nucl Med. 2004 Apr; 45(4):571-8. PMID: 15073252.
      View in: PubMed
    5. Abdalla I, Ignacio L, Vaida F. Evolution of toxicity after conformal radiotherapy for prostate cancer. Prostate Cancer Prostatic Dis. 2002; 5(4):296-303. PMID: 12627215.
      View in: PubMed
    6. Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW, Roach M, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001 Dec 20; 96(6):363-71. PMID: 11745507.
      View in: PubMed
    7. Connell PP, Ignacio L, Haraf D, Awan AM, Halpern H, Abdalla I, Nautiyal J, Jani AB, Weichselbaum RR, Vijayakumar S. Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J Clin Oncol. 2001 Jan 01; 19(1):54-61. PMID: 11134195.
      View in: PubMed
    8. Chung TD, Park II, Ignacio L, Catchatourian R, Kopnick M, Davison E, Conrad G, Awan AM, Crawford D, Vijayakumar S. Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial. Int J Cancer. 2000 Oct 20; 90(5):302-4. PMID: 11091355.
      View in: PubMed
    9. Jani AB, Chen MH, Vaida F, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S. PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention. Urology. 1999 Oct; 54(4):700-5. PMID: 10510931.
      View in: PubMed
    10. Mantz CA, Nautiyal J, Awan A, Kopnick M, Ray P, Kandel G, Niederberger C, Ignacio L, Dawson E, Fields R, Weichselbaum R, Vijayakumar S. Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am. 1999 Jul-Aug; 5(4):230-6. PMID: 10439169.
      View in: PubMed
    11. Mantz CA, Song P, Farhangi E, Nautiyal J, Awan A, Ignacio L, Weichselbaum R, Vijayakumar S. Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Feb 01; 37(3):551-7. PMID: 9112452.
      View in: PubMed
    12. Mundt AJ, Awan A, Sibley GS, Simon M, Rubin SJ, Samuels B, Wong W, Beckett M, Vijayakumar S, Weichselbaum RR. Conservative surgery and adjuvant radiation therapy in the management of adult soft tissue sarcoma of the extremities: clinical and radiobiological results. Int J Radiat Oncol Biol Phys. 1995 Jul 15; 32(4):977-85. PMID: 7607972.
      View in: PubMed
    13. Vijayakumar S, Roach M, Wara W, Chan SK, Ewing C, Rubin S, Sutton H, Halpern H, Awan A, Houghton A, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial. Int J Radiat Oncol Biol Phys. 1993 Jul 15; 26(4):721-9. PMID: 8331011.
      View in: PubMed
    14. Vogelzang NJ, Moormeier JA, Awan AM, Weichselbaum RR, Farah R, Straus FH, Schoenberg HW, Chodak GW. Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience. J Urol. 1993 Apr; 149(4):753-7. PMID: 8455237.
      View in: PubMed
    15. Vijayakumar S, Awan A, Karrison T, Culbert H, Chan S, Kolker J, Low N, Halpern H, Rubin S, Chen GT, et al. Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques. Int J Radiat Oncol Biol Phys. 1993 Jan 15; 25(2):359-71. PMID: 8420886.
      View in: PubMed
    16. Vijayakumar S, Karrison T, Weichselbaum RR, Chan S, Quadri SF, Awan AM. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec; 1(7):541-5. PMID: 1284591.
      View in: PubMed
    17. Vijayakumar S, Low N, Chen GT, Myrianthopoulos L, Culbert H, Chiru P, Spelbring D, Awan A, Rosenberg I, Halpern H, et al. Beams eye view-based photon radiotherapy I. Int J Radiat Oncol Biol Phys. 1991 Nov; 21(6):1575-86. PMID: 1657844.
      View in: PubMed
    18. Awan AM, Vokes EE, Weichselbaum RR. Recent advances in radiation therapy for head and neck cancer. Hematol Oncol Clin North Am. 1991 Aug; 5(4):635-55. PMID: 1890057.
      View in: PubMed
    19. Vokes EE, Awan AM, Weichselbaum RR. Radiotherapy with concomitant chemotherapy for head and neck cancer. Hematol Oncol Clin North Am. 1991 Aug; 5(4):753-67. PMID: 1890065.
      View in: PubMed
    20. Farah R, Chodak GW, Vogelzang NJ, Awan AM, Quiet CA, Moormeier J, Schoenberg H, Weichselbaum RR. Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report). Int J Radiat Oncol Biol Phys. 1991 Mar; 20(3):413-7. PMID: 1995525.
      View in: PubMed
    21. Awan AM, Weichselbaum RR. Palliative radiotherapy. Hematol Oncol Clin North Am. 1990 Dec; 4(6):1169-81. PMID: 1704880.
      View in: PubMed
    22. Weichselbaum RR, Beckett MA, Vijayakumar S, Simon MA, Awan AM, Nachman J, Panje WR, Goldman ME, Tybor AG, Moran WJ, et al. Radiobiological characterization of head and neck and sarcoma cells derived from patients prior to radiotherapy. Int J Radiat Oncol Biol Phys. 1990 Aug; 19(2):313-9. PMID: 2394610.
      View in: PubMed
    23. Hallahan DE, Michel AG, Halpern HJ, Awan AM, Desser R, Bitran J, Recant W, Wyman B, Spelbring DR, Weichselbaum RR. Breast conserving surgery and definitive irradiation for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1989 Dec; 17(6):1211-6. PMID: 2557305.
      View in: PubMed
    24. Vokes EE, Panje WR, Schilsky RL, Mick R, Awan AM, Moran WJ, Goldman MD, Tybor AG, Weichselbaum RR. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989 Jun; 7(6):761-8. PMID: 2715806.
      View in: PubMed
    25. Weichselbaum RR, Beckett MA, Simon MA, McCauley C, Haraf D, Awan A, Samuels B, Nachman J, Dritschilo A. In vitro radiobiological parameters of human sarcoma cell lines. Int J Radiat Oncol Biol Phys. 1988 Oct; 15(4):937-42. PMID: 3182333.
      View in: PubMed
    26. Vokes EE, Panje WR, Weichselbaum RR, Schilsky RL, Moran WJ, Awan AM, Guarnieri CM. Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. Otolaryngol Head Neck Surg. 1988 Apr; 98(4):295-8. PMID: 3132681.
      View in: PubMed
    27. Vokes EE, Moran WJ, Awan AM, Schilsky RL, Goldman M, Sutton HG, Weichselbaum RR, Panje WR. Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6. PMID: 3352782.
      View in: PubMed
    Awan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _